Debevoise Advises Capital Group in its Investment in Intas Pharmaceuticals

6 April 2017

The Hong Kong office of Debevoise & Plimpton has advised Capital Group in its acquisition of an equity stake in Intas Pharmaceuticals Limited (“Intas”), one of the largest pharmaceutical companies in India, from ChrysCapital, an India-focused private equity firm, through a competitive auction process.

Intas is headquartered in India and has operations across the world, including in the U.S. and the UK. Intas is primarily focused on manufacturing and marketing pharmaceutical formulations. Moelis & Company India acted as the financial advisor to ChrysCapital and ran the auction process.

Capital Group - Private Markets is a leading private equity investor in emerging markets with over two decades of experience and has invested over $5 billion in more than 80 countries across global emerging markets.

The Hong Kong-based Debevoise team advising Capital Group was led by partner William Y. Chua and law clerk Monisha D’Souza, assisted by international counsel Brian McKenna. New York partner Andrew M. Levine and Shanghai counsel Philip Rohlik advised on anti-bribery and anti-corruption law compliance matters, while New York counsel Carl Micarelli and Washington D.C. associate Robert T. Dura provided sanctions related advice. Tax advice was provided by New York partner Peter Furci, and EU competition law advice was provided by international counsel Timothy McIver in London.